Clinical trial
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With…
NCT00034918 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00034918 |
|---|---|
| Title | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer |
| Official title | An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose). |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | ZD6474 |
| Enrollment | 44 |
| Start date | May 1, 2002 |
| Completion | Nov 1, 2003 |
| First posted | May 3, 2002 |
| Last update posted | Aug 24, 2016 |
| Countries | Spain, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: